STL Index for: Hyaluronic Acid

Moisturizers and Cleansers in the Management of Skin Conditions Caused by Personal Protective Equipment and Frequent Handwashing

Routine moisturization with non-irritating, pH-adjusted, ceramide-based products and gentle cleansing with a pH-adjusted cleanser can treat the unique dermatological challenges posed by COVID-19.

Platelet-Rich Plasma (PRP): Current Applications in Dermatology

Platelet-rich plasma (PRP) is an autologous serum containing high concentrations of platelets and growth factors. PRP continues to evolve as an important treatment modality with many applications in dermatology, particularly in the areas of hair restoration, skin rejuvenation, acne scars, dermal augmentation, and striae distensae.

Steroid-Sparing Properties of Emollients in Dermatology

This article reviews topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) to manage inflammatory conditions, its risks with long-term use, and the role of moisturizing as important therapeutic adjuncts.

Skin Treatments Introduced in 2012

Skin Treatments Introduced in 2012. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US), Ingenol mebutate gel (0.015%, 0.05%) Picato®and more are covered.

Skin Treatments Introduced in 2012

An overview and update of skin treatments introduced in 2012: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US) and more drugs are covered.

Skin Treatments Introduced in 2011

An overview and update of skin treatments introduced in 2011: Adapalene 0.1% + benzoyl peroxide 2.5% gel (Tactuo™), 5-fluorouracil cream 0.5% + salicylic acid 10% (Actikerall®), Autologous cell therapy dermal filler laVív® (azficel-T) and more drugs are covered.

Drug Treatments for Skin Disease Introduced in 2010

An overview and update of skin conditions and treatments introduced in 2010: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% lotion (Differin®), Clindamycin phosphate 1.2% + tretinoin 0.025% gel (Veltin™) and many other drugs are covered.

Drug Treatments for Skin Disease Introduced in 2010

Drug Treatments for Skin Disease Introduced in 2010. Adapalene 0.1% lotion (Differin®), Drospirenone / ethinyl estradiol / levomefolate calcium + levomefolate calcium tablets (Beyaz™) and many other drugs are covered.

Nanodermatology: A Bright Glimpse Just Beyond the Horizon – Part I

Nanotechnology is a relatively new branch of engineering that is making rapid inroads in medicine and dermatology. This article summarizes some of the recent and anticipated advances in nanotechnology for dermatology. In part II, the author addresses the chief concerns of nanotechnology.

Update on Drugs and Drug News: March 2010

Update on Hyaluronic acid dermal filler + 0.3% lidocaine JUVÉDERM® XC, Hyaluronic acid dermal filler + 0.3% lidocaine RESTYLANE®-L PERLANE®-L, and news on labeling changes regarding possible hepatic effects of diclofenac sodium topical gel 1% (Voltaren® Gel).

Drug Treatments for Skin Disease Introduced in 2007

Treatments introduced in 2007 including Adapalene Gel 0.3% Differin®, Drospirenone/ Ethinyl Estradiol Yaz®, Tretinoin 0.05% Gel Anthralin®, Daptomycin for Injection CUBICIN®, Retapamulin Ointment 1% Altabax®, Tinidazole Tablets Tindamax® and other treatments.

Non-Surgical Treatment of Acne Scars

Acne scars are challenging to treat. This article discusses the non-surgical treatment options like topical treatments, chemical peels, skin fillers, cover-ups, and injectables.

Dermal Fillers: Ever-Expanding Options For Esthetic Use

Aesthetic volume rejuvenation with dermal fillers continues to be a popular procedure that is sought by a growing number of patients who seek the rounder softer contours attributable to a more youthful appearance. This article will focus on the most popular, time tested, and innovative fillers available today.

Treatment of Acne Scarring

Acne scarring is common but surprisingly difficult to treat. Scars can involve textural change in the superficial and deep dermis, and can also be associated with erythema, and less often, pigmentary change. In general, treatment of acne scarring is a multistep procedure.

Moisturizers: What They Are and a Practical Approach to Product Selection

Moisturizers are widely used products that are important in many dermatologic and cosmetic skin therapies. They contain varying combinations of emollients, occlusives, and humectants to achieve their beneficial effects, and there is an overwhelming number of formulations available.

Imiquimod 5% Cream for the Treatment of Actinic Keratoses

Actinic keratoses (AKs) are premalignant inflammatory skin lesions with the potential to transform into squamous cell carcinoma (SCC). There are several treatment options available for patients presenting with multiple AKs. Imiquimod is believed to stimulate and enhance host immune responses locally against skin tumors and viral infections.

Clinical Use of RESTYLANE®

There is no ideal filler, nor will there be a single product that can satisfy all requirements. However, RESTYLANE®, a non-animal, stabilized hyaluronic acid (NASHA, Medicis), is a very versatile augmenting agent. It has been in clinical use for 8 years and experience has shown it to be close to the ideal filler in many respects.

Topical 3% Diclofenac in 2.5% Hyaluronan Gel for the Treatment of Actinic Keratoses

Many of the treatment options available can cause discomfort, pain or skin irritation. Topical 3% diclofenac in 2.5% hyaluronan gel (Solaraze™, Bioglan Pharma) is a relatively new treatment that has been shown to be effective and well tolerated for the treatment of AKs.

POPULAR